[Click eStock] "Raijeo Optek, Expected Earnings Improvement Due to Stabilization of US Corporation"

Hana Securities on the 24th forecasted that Laseroptek will enter the early growth phase due to the stabilization of its U.S. subsidiary.

Seongho Kim, a researcher at Hana Securities, explained, "Laseroptek's business structure is not like domestic beauty medical device companies that supply consumables after equipment sales," adding, "It is a company that grows by launching new products every year."

He continued, "We expect growth as they release high value-added devices focused on disease treatment equipment," emphasizing, "Disease treatment devices have fewer competitors compared to skin beauty medical devices and have high technological entry barriers, resulting in a higher average selling price (ASP)."

He said, "The Palas premium export price is more than three times that of existing skin beauty medical device equipment," and added, "Palas premium officially started marketing at the American Academy of Dermatology in March this year." He also noted, "The indications approved by the U.S. Food and Drug Administration (FDA) include psoriasis, vitiligo, and atopic dermatitis."

Researcher Kim stated, "Raman Laser is the world's first vascular treatment device capable of treating vascular lesions," and predicted, "After its domestic release in the second half of next year, it will be launched in the U.S. and overseas markets in 2026." He expressed expectations for the Thulium Fiber, describing it as "a laser-based urinary stone treatment device," and said, "It is scheduled for release in 2027."

Kim emphasized, "Starting next year, we expect sales normalization through the expansion of the new product portfolio and normal operations of the U.S. subsidiary," adding, "The U.S. subsidiary has stabilized, and the export ratio is rapidly increasing."

This content was produced with the assistance of AI translation services.